adrenergic 3

Question 1

Milrinone mechanism

Answer 1

1. PDE inhibitor
2. augments myocyte Ca utilization,
3. moderate peripheral vasodilation

Question 2

Milrinone indication

Answer 2

ADHF short-term management - “Cold & wet”

Question 3

Milrinone half life

Answer 3

1 hour, prolonged 2-3 hours if CrCl < 50 ml/min

Question 4

Milrinone is recommended if

Answer 4

if receiving a B-blocker.

Question 5

Milrinone side effects

Answer 5

1. Hypotension,
2. Thrombocytopenia,
3. Tachycardia,
4. Arrhythmias,
5. Fever,
6. Increased LFTs

Question 6

inotropic agents are indicated for pt with

Answer 6

advanced HF and low output sydrome (LV dilation, reduced, decrease end organ dysfucntion)

Question 7

inotropic agents are used to

Answer 7

1. To relieve symptoms and improve end-organ function
2. Patients with marginal systolic blood pressure (<90 mm Hg)
3. Patients with symptomatic hypotension despite adequate filling pressure
4. Unresponsive to, or intolerant of, intravenous vasodilators

Question 8

Dopamine mechanism

Answer 8

endogenous precursor of norepinephrine-
excerts its effects by directly stimulating adrenergic
receptors, as well as, release norepi from nerve
terminals

Question 9

Dopamine adverse effects

Answer 9

1. arrythmia
2. angina
3. increased heart rate
4. increased mean arterial pressure
5. Increased systemic vasculature